Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Authors:
- Alice T ShawASAlice T Shaw
- Benjamin J SolomonBSBenjamin J Solomon
- 12 February 2015
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 372 (7) , 683-684
Abstract
In the study reported by Shaw et al. (Nov. 20 issue),1 crizotinib appears to be more potent against the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) than against anaplastic lymphoma kinase (ALK) in non–small-cell lung cancers (NSCLCs), at least in vitro. The study also showed no apparent pharmacokinetic differences between patients with ALK rearrangements and those with ROS1 rearrangements. It would be interesting to know how many (if any) patients received a dose reduction of crizotinib, as well as the outcomes in these patients.Keywords
This publication has 5 references indexed in Scilit:
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2014
- Prognosis in Patients with Non-Small Cell Lung Cancer Who Received Erlotinib Treatment and Subsequent Dose Reduction due to Skin RashOnkologie, 2012
- Flushing Oral Oncology Drugs Down the ToiletJournal of Clinical Oncology, 2011
- Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR MutationsJournal of Thoracic Oncology, 2010
- Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous ToxicityJournal of Thoracic Oncology, 2009